265 studies found for:    Open Studies | "Carcinoma, Renal Cell"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Carcinoma, Renal Cell" (265 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Not yet recruiting Immunotherapy Study for Metastatic Renal Cell Cancer
Conditions: Metastatic Renal Cell Carcinoma;   Metastatic Clear-cell Renal Cancer;   Recurrent Renal Cell Carcinoma;   Refractory Renal Cell Carcinoma;   Metastatic Kidney Cancer
Intervention: Biological: HyperAcute®-Renal (HAR) Immunotherapy
2 Recruiting AMG 172 First in Human Study in Patients With Kidney Cancer
Conditions: Renal Cell Adenocarcinoma;   Clear Cell Renal Carcinoma;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Intervention: Drug: AMG 172
3 Recruiting A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
Conditions: Carcinoma, Renal Cell;   Renal Cell Carcinoma With Clear Cell Histology;   Renal Cell Carcinoma With Non-Clear Cell Histology;   Renal Cell Carcinoma of Papillary Histology
Intervention: Drug: AGS-16C3F
4 Recruiting Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Biological: bevacizumab;   Biological: anti-endoglin monoclonal antibody TRC105;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Recruiting Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: ziv-aflibercept;   Other: laboratory biomarker analysis
6 Recruiting Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Intervention: Drug: pazopanib hydrochloride
7 Recruiting Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: panobinostat;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: liquid chromatography;   Other: mass spectrometry;   Other: enzyme-linked immunosorbent assay;   Other: immunohistochemistry staining method
8 Unknown  Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250
Conditions: Renal Cell Carcinoma;   Kidney Neoplasm;   Renal Cancer;   Kidney Cancer
Intervention: Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)
9 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
10 Recruiting Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Genetic: mutation analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Drug: sunitinib malate;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
11 Recruiting Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Conditions: Advanced Renal Cell Carcinoma;   Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment;   Biological: AGS-003
12 Not yet recruiting Perfusion CT in Predicting Response to Treatment in Patients With Advanced Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: perfusion;   Procedure: computed tomography;   Other: laboratory biomarker analysis
13 Recruiting Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Other: pharmacogenomic studies
14 Not yet recruiting Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Radiation: stereotactic body radiation therapy;   Drug: cyclophosphamide;   Biological: therapeutic autologous lymphocytes;   Other: laboratory biomarker analysis
15 Recruiting Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: AdGMCAIX-transduced autologous dendritic cells;   Biological: therapeutic autologous dendritic cells;   Other: laboratory biomarker analysis
16 Recruiting Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: cabozantinib-s-malate;   Drug: sunitinib malate;   Other: laboratory biomarker analysis
17 Recruiting Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Procedure: therapeutic conventional surgery
18 Recruiting Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: trebananib;   Biological: bevacizumab;   Drug: pazopanib hydrochloride;   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: laboratory biomarker analysis;   Other: pharmacological study
19 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Other: placebo;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: pharmacological study
20 Recruiting Interleukin-2 in Metastatic Kidney Cancer
Conditions: Renal Cell Cancer Metastatic;   Kidney Cancer Metastatic
Intervention: Drug: Interleukin-2

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years